In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung ...

Chronic obstructive pulmonary disease (COPD) is characterized by a chronic airflow obstruction that is associated with severe global mortality and morbidity. A team of researchers from USA, led by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

Although overall prevalence and death rates for asthma and chronic obstructive pulmonary disease (COPD) declined between 1990 and 2015, population growth and aging have driven up worldwide numbers for ...

"The key finding as a clinician is to recognize that severe COPD patients have heterogeneity in terms of biological processes, which likely explains variable clinical courses and responses to ...

A lung disease impacting more than 16 million Americans has no long-term fix, but a new treatment could help. Piedmont Atlanta is the first hospital in Georgia to offer a new, minimally invasive ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...